Biosimilar Competition and Patient Out-of-Pocket Costs
By Staff Writer
May 6, 2024
Introduction
The American healthcare landscape is witnessing a significant shift with the introduction of biosimilars, designed to create market competition and reduce the financial burden of biologic medications. In 2021, patients and payers in the US spent over $500 billion on prescription drugs, with biologics representing a substantial portion of these costs. This article examines the impact of biosimilar competition on out-of-pocket (OOP) costs for patients using biologics including filgrastim, infliximab, pegfilgrastim, epoetin alfa, bevacizumab, rituximab, and trastuzumab.
Understanding Biosimilars
Biosimilars are analogous to generic drugs but for complex biologic medications. The rationale for their introduction is to provide a cost-effective alternative to expensive brand-name biologics, once patent protections expire. With prices typically 15% to 35% lower, biosimilars are poised to deliver significant savings to the healthcare system. In January 2021, there was just one biosimilar available for epoetin alfa, whereas the other six biologics had a minimum of two biosimilars, with trastuzumab having the highest number of five.
The Cost Conundrum
Infliximab accounted for 31% of patient-years, making it the most often utilised biologic. Conversely, epoetin alfa constituted a mere 3% of patient-years, rendering it the least commonly employed. Despite the potential for reduced costs, the real-world impact on individual patient OOP expenses remains ambiguous. Insurance benefit designs, reimbursement rates, and the timing of deductible fulfilment all contribute to the complexity of assessing biosimilar competition’s direct effect on patient costs.
The Study’s Findings
A recent analysis focused on commercially insured patients using seven clinician-administered biologics with available biosimilars. The results revealed a trend towards increased OOP costs post-biosimilar introduction, challenging the assumption that biosimilars would automatically lead to lower patient expenses.
Figure 1. Trends in Annual Out-of-Pocket (OOP) Spending for Biologic Drugs, Before and After Biosimilar Availability
Variations in Out-of-Pocket Costs
The study highlighted that the influence of biosimilar competition on OOP costs is not uniform across all biologics. While some drugs showed a decrease in OOP expenses following biosimilar entry, others exhibited an increase or no significant change, underscoring the complexity of the issue. Claims for biosimilar infliximab had higher OOP costs than the reference biologic (AOR, 1.22), while claims for bevacizumab showed the opposite tendency (AOR, 0.77).
Figure 2. Differences in Out-of-Pocket (OOP) Spending Between Claims for Biosimilars and Reference Biologics
The Disconnect Between Savings and Patient Costs
Despite biosimilars generating nearly $13 billion in savings, these have not translated into lower OOP costs for patients. The study suggests that while biosimilar competition may reduce overall healthcare spending and potentially lower premiums, these benefits do not directly impact individual patient costs.
Biosimilar Competition and Patient Costs
Previous biosimilar-OOP cost studies were inconsistent. Filgrastim found that biosimilar introduction lowered monthly OOP costs only for high-deductible plans. Infliximab biosimilar trials showed a minor decrease in OOP expenses per claim, but higher annual spending owing to cost-sharing and lack of discounts. Biosimilar users had decreased OOP costs per cycle, according to pegfilgrastim studies. The findings underscore the need for regulatory measures to ensure that biosimilar savings enhance patient affordability and access. Policymakers could consider laws to limit OOP expenses for biosimilars or decouple patient cost-sharing from inflated reimbursement rates.
Conclusion
The introduction of biosimilars represents a promising strategy to contain healthcare costs. However, this article indicates that, thus far, biosimilar competition has not consistently lowered the OOP costs for patients using biologics. It is imperative for policymakers to implement strategies that ensure the economic benefits of biosimilars extend to patients, enhancing affordability and access to essential medications.
🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?
The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.
Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.
In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.
Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!
💡 Are you ready for a potential game-changer in drug pricing transparency?
CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.
Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!
#SyenzaNews #healthcare #HealthEconomics
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.